Table 1 Patient clinical outcomes hemotoxic mast cell stain
From: Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
| Â | N (% of total 36 patients) |
|---|---|
Stage | Â |
IIIA | 1 (3%) |
IIIB | 5 (14%) |
IIIC | 25 (69%) |
IV | 5 (14%) |
Recurred | Â |
Yes | 32 (89%) |
No | 4 (11%) |
Overall Survival Status | Â |
Living | 11 (30%) |
Deceased | 23 (64%) |
Lost to Follow up | 1 (3%) |
Deceased not from HGSOC | 1 (3%) |
| Â | Median [Range] |
Age at Diagnosis | 63 [46–79] |
PFS (months) | 16 [6–51] |
OS (months) | 40 [12–83] |